{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T13:12:22Z","timestamp":1775826742821,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chinese Institutes for Medical Research","award":["CX24PY24"],"award-info":[{"award-number":["CX24PY24"]}]},{"name":"Beijing Public Health Experts Project","award":["G2023-2-002"],"award-info":[{"award-number":["G2023-2-002"]}]},{"name":"R&D Program of Beijing Municipal Education Commission","award":["KZ20231002545"],"award-info":[{"award-number":["KZ20231002545"]}]},{"name":"The Beijing High-Level Public Health Talent Program","award":["G2024-03-08"],"award-info":[{"award-number":["G2024-03-08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04170-w","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T03:14:43Z","timestamp":1772680483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase therapy regimen containing clofazimine manifested high efficacy in treating Mycobacterium abscessus pulmonary disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Shengjuan","family":"Bao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hairong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongfei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"1","key":"4170_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40249-021-00844-1","volume":"10","author":"CF Liu","year":"2021","unstructured":"Liu CF, Song YM, He WC, et al. Nontuberculous mycobacteria in china: incidence and antimicrobial resistance spectrum from a nationwide survey. Infect Dis Poverty. 2021;10(1):59.","journal-title":"Infect Dis Poverty"},{"key":"4170_CR2","doi-asserted-by":"crossref","unstructured":"Daley CL, Iaccarino JM, Lange C et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur Respir J 2020;56(1).","DOI":"10.1183\/13993003.00535-2020"},{"key":"4170_CR3","doi-asserted-by":"crossref","unstructured":"Kwak N, Dalcolmo MP, Daley CL et al. M Ycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J 2019;54(1).","DOI":"10.1183\/13993003.01991-2018"},{"key":"4170_CR4","doi-asserted-by":"crossref","unstructured":"Pasipanodya JG, Ogbonna D, Ferro BE et al. Systematic review and Meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Antimicrob Agents Chemother 2017;61(11).","DOI":"10.1128\/AAC.01206-17"},{"issue":"1","key":"4170_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","volume":"161","author":"DE Griffith","year":"2022","unstructured":"Griffith DE, Daley CL. Treatment of Mycobacterium abscessus pulmonary disease. Chest. 2022;161(1):64\u201375.","journal-title":"Chest"},{"issue":"5","key":"4170_CR6","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","volume":"182","author":"A Van Deun","year":"2010","unstructured":"Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684\u201392.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"4170_CR7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijantimicag.2009.12.008","volume":"35","author":"GH Shen","year":"2010","unstructured":"Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH. High efficacy of Clofazimine and its synergistic effect with Amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents. 2010;35(4):400\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"4170_CR8","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1128\/AAC.01505-12","volume":"56","author":"J van Ingen","year":"2012","unstructured":"van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In vitro synergy between Clofazimine and Amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012;56(12):6324\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"4170_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1128\/AAC.00072-18","volume":"62","author":"JJ Luo","year":"2018","unstructured":"Luo JJ, Yu X, Jian G, et al. In vitro activity of Clofazimine against nontuberculous mycobacteria isolated in Beijing, China. Antimicrob Agents Chemother. 2018;62(7):9.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4170_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.chest.2020.07.040","volume":"159","author":"N Kwak","year":"2021","unstructured":"Kwak N, Whang J, Yang JS, Kim TS, Kim SA, Yim JJ. Minimal inhibitory concentration of Clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcome. Chest. 2021;159(2):517\u201323.","journal-title":"Chest"},{"issue":"1","key":"4170_CR11","doi-asserted-by":"publisher","first-page":"dlab004","DOI":"10.1093\/jacamr\/dlab004","volume":"3","author":"T Asami","year":"2021","unstructured":"Asami T, Aono A, Chikamatsu K, et al. Efficacy Estimation of a combination of triple antimicrobial agents against clinical isolates of Mycobacterium Abscessus subsp. Abscessus in vitro. JAC-antimicrobial Resist. 2021;3(1):dlab004.","journal-title":"JAC-antimicrobial Resist"},{"issue":"5","key":"4170_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1128\/AAC.02131-20","volume":"65","author":"B Schulthess","year":"2021","unstructured":"Schulthess B, Schafle D, Kalin N, Widmer T, Sander P. Drug susceptibility distributions of Mycobacterium chimaera and other nontuberculous mycobacteria. Antimicrob Agents Chemother. 2021;65(5):9.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"4170_CR13","doi-asserted-by":"publisher","first-page":"ofx147","DOI":"10.1093\/ofid\/ofx147","volume":"4","author":"SA McGuffin","year":"2017","unstructured":"McGuffin SA, Pottinger PS, Harnisch JP. Clofazimine in nontuberculous mycobacterial infections: A growing niche. Open Forum Infect Dis. 2017;4(3):ofx147.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"4170_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jac\/dkr444","volume":"67","author":"MC Cholo","year":"2012","unstructured":"Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. Clofazimine: current status and future prospects. J Antimicrob Chemother. 2012;67(2):290\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"4170_CR15","doi-asserted-by":"publisher","first-page":"O1124","DOI":"10.1111\/1469-0691.12780","volume":"20","author":"S Singh","year":"2014","unstructured":"Singh S, Bouzinbi N, Chaturvedi V, Godreuil S, Kremer L. In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex. Clin Microbiol Infection: Official Publication Eur Soc Clin Microbiol Infect Dis. 2014;20(12):O1124\u20131127.","journal-title":"Clin Microbiol Infection: Official Publication Eur Soc Clin Microbiol Infect Dis"},{"issue":"2","key":"4170_CR16","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1128\/AAC.02615-15","volume":"60","author":"BE Ferro","year":"2016","unstructured":"Ferro BE, Meletiadis J, Wattenberg M, et al. Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to Amikacin and clarithromycin. Antimicrob Agents Chemother. 2016;60(2):1097\u2013105.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4170_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijantimicag.2014.09.012","volume":"45","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Li T, Qu G, Pang Y, Zhao Y. In vitro synergistic activity of Clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents. 2015;45(1):71\u20135.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"4170_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1128\/AAC.02349-19","volume":"64","author":"JP Lanoix","year":"2020","unstructured":"Lanoix JP, Joseph C, Peltier F, Castelain S, Andrejak C. Synergistic activity of Clofazimine and clarithromycin in an aerosol mouse model of Mycobacterium avium infection. Antimicrob Agents Chemother. 2020;64(5):5.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"4170_CR19","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1128\/JCM.00612-11","volume":"49","author":"C Bicmen","year":"2011","unstructured":"Bicmen C, Gunduz AT, Coskun M, Senol G, Cirak AK, Ozsoz A. Molecular detection and identification of Mycobacterium tuberculosis complex and four clinically important nontuberculous mycobacterial species in smear-negative clinical samples by the genotype mycobacteria direct test. J Clin Microbiol. 2011;49(8):2874\u20138.","journal-title":"J Clin Microbiol"},{"issue":"Pt 4","key":"4170_CR20","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1099\/ijs.0.63553-0","volume":"55","author":"H Kim","year":"2005","unstructured":"Kim H, Kim SH, Shim TS, et al. Differentiation of Mycobacterium species by analysis of the heat-shock protein 65 gene (hsp65). Int J Syst Evol Microbiol. 2005;55(Pt 4):1649\u201356.","journal-title":"Int J Syst Evol Microbiol"},{"issue":"Pt 12","key":"4170_CR21","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1099\/mic.0.2008\/020164-0","volume":"154","author":"I Ben Salah","year":"2008","unstructured":"Ben Salah I, Ad\u00e9kambi T, Raoult D, Drancourt M. RpoB sequence-based identification of Mycobacterium avium complex species. Microbiol (Reading). 2008;154(Pt 12):3715\u201323.","journal-title":"Microbiol (Reading)"},{"issue":"9","key":"4170_CR22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1164\/rccm.200905-0704OC","volume":"180","author":"K Jeon","year":"2009","unstructured":"Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009;180(9):896\u2013902.","journal-title":"Am J Respir Crit Care Med"},{"key":"4170_CR23","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.2147\/IDR.S408986","volume":"16","author":"R Zhang","year":"2023","unstructured":"Zhang R, Luo S, Wang N, Zhang H, Wu X. Epidemiology of nontuberculous mycobacteria in Nanjing and MAB_0540 mutations associated with Clofazimine resistance in Mycobacterium abscessus. Infect Drug Resist. 2023;16:2751\u201364.","journal-title":"Infect Drug Resist"},{"issue":"1","key":"4170_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12941-023-00655-2","volume":"22","author":"LP Cheng","year":"2023","unstructured":"Cheng LP, Zhang Q, Lou H, et al. Effectiveness and safety of regimens containing linezolid for treatment of Mycobacterium abscessus pulmonary disease. Ann Clin Microbiol Antimicrob. 2023;22(1):106.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"4170_CR25","doi-asserted-by":"publisher","first-page":"8631563","DOI":"10.1155\/2019\/8631563","volume":"2019","author":"H Li","year":"2019","unstructured":"Li H, Tong L, Wang J, et al. An intensified regimen containing linezolid could improve treatment response in Mycobacterium abscessus lung disease. Biomed Res Int. 2019;2019:8631563.","journal-title":"Biomed Res Int"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04170-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04170-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04170-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:01:27Z","timestamp":1775822487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04170-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4170"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04170-w","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted following the Declaration of Helsinki. The Institutional Review Board of Beijing Chest Hospital, Capital Medical University, approved the protocol (IRB No. YJS-2022-15). This trial was retrospectively registered at ClinicalTrials.gov on November 8, 2024 (Registration number: [ChiCTR2400092512]). All patients who enrolled prospectively in this study provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from the patient(s) (or their legal guardians) from whom the bacterial strains were isolated.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}